BR112022010774A2 - Uso de nucleossomos livres de células como biomarcadores - Google Patents

Uso de nucleossomos livres de células como biomarcadores

Info

Publication number
BR112022010774A2
BR112022010774A2 BR112022010774A BR112022010774A BR112022010774A2 BR 112022010774 A2 BR112022010774 A2 BR 112022010774A2 BR 112022010774 A BR112022010774 A BR 112022010774A BR 112022010774 A BR112022010774 A BR 112022010774A BR 112022010774 A2 BR112022010774 A2 BR 112022010774A2
Authority
BR
Brazil
Prior art keywords
biomarkers
cell
free nucleosomes
nucleosomes
free
Prior art date
Application number
BR112022010774A
Other languages
English (en)
Portuguese (pt)
Inventor
Vincent Micallef Jacob
Wilson-Robles Heather
Edward Eccleston Mark
Chantal Andree Herzog Marielle
Bradley Terrell Jason
Original Assignee
Belgian Volition Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition Srl filed Critical Belgian Volition Srl
Publication of BR112022010774A2 publication Critical patent/BR112022010774A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022010774A 2019-12-02 2020-12-02 Uso de nucleossomos livres de células como biomarcadores BR112022010774A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942596P 2019-12-02 2019-12-02
US202063088408P 2020-10-06 2020-10-06
PCT/EP2020/084328 WO2021110776A1 (en) 2019-12-02 2020-12-02 Use of cell free nucleosomes as biomarkers

Publications (1)

Publication Number Publication Date
BR112022010774A2 true BR112022010774A2 (pt) 2022-08-23

Family

ID=73698838

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010774A BR112022010774A2 (pt) 2019-12-02 2020-12-02 Uso de nucleossomos livres de células como biomarcadores

Country Status (15)

Country Link
US (1) US20230003735A1 (enExample)
EP (2) EP4435431A3 (enExample)
JP (2) JP7693670B2 (enExample)
KR (1) KR102930652B1 (enExample)
CN (1) CN114829939B (enExample)
AU (1) AU2020395504A1 (enExample)
BR (1) BR112022010774A2 (enExample)
CA (1) CA3163181A1 (enExample)
ES (1) ES2988371T3 (enExample)
IL (1) IL293342B2 (enExample)
MX (1) MX2022006655A (enExample)
PL (1) PL4070111T3 (enExample)
TW (1) TWI902730B (enExample)
WO (1) WO2021110776A1 (enExample)
ZA (1) ZA202205916B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4155401A1 (en) * 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2015138774A1 (en) 2014-03-13 2015-09-17 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
US20250197944A1 (en) 2022-03-11 2025-06-19 Belgian Volition Srl Differential diagnosis method
EP4577833A1 (en) 2022-08-25 2025-07-02 Belgian Volition SRL Method for measuring cell free chromatin
EP4639173A1 (en) * 2022-12-19 2025-10-29 Belgian Volition SRL Calibration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
GB0413732D0 (en) * 2004-06-13 2004-07-21 Chroma Therapeutics Ltd Histone modification
ATE534908T1 (de) * 2009-08-03 2011-12-15 Universitaetsklinikum Freiburg Verfahren und verbindungen zur diagnose und behandlung von krebs
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
JP6263474B2 (ja) 2011-12-07 2018-01-17 シンガポール ボリション ピーティーイー リミテッド ヌクレオソームアダクト検出法
EP4155401A1 (en) * 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9388213B2 (en) * 2012-09-10 2016-07-12 The Rockefeller University Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
SG11201702978VA (en) 2014-10-29 2017-05-30 Belgian Volition Sprl Method for the enrichment of circulating tumor dna
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201518674D0 (en) 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
CN111918971B (zh) * 2018-03-01 2024-09-03 埃皮塞弗公司 利用化学确定的重组核小体定量核小体修饰

Also Published As

Publication number Publication date
CA3163181A1 (en) 2021-06-10
JP7693670B2 (ja) 2025-06-17
JP2023503379A (ja) 2023-01-27
IL293342B2 (en) 2026-05-01
EP4435431A2 (en) 2024-09-25
EP4070111B1 (en) 2024-08-21
TW202134654A (zh) 2021-09-16
IL293342B1 (en) 2026-01-01
ES2988371T3 (es) 2024-11-20
EP4070111C0 (en) 2024-08-21
CN114829939A (zh) 2022-07-29
AU2020395504A1 (en) 2022-06-23
PL4070111T3 (pl) 2025-02-03
ZA202205916B (en) 2024-09-25
KR102930652B1 (ko) 2026-02-25
EP4070111A1 (en) 2022-10-12
WO2021110776A1 (en) 2021-06-10
MX2022006655A (es) 2022-09-07
US20230003735A1 (en) 2023-01-05
KR20220110794A (ko) 2022-08-09
CN114829939B (zh) 2025-10-21
TWI902730B (zh) 2025-11-01
EP4435431A3 (en) 2024-10-16
JP2025124845A (ja) 2025-08-26
IL293342A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
EP4567127A3 (en) Methods for determining a location of a biological analyte in a biological sample
EP4234689A3 (en) Split inteins with exceptional splicing activity
ZA202205916B (en) Use of cell free nucleosomes as biomarkers
MX2015013202A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX356986B (es) Metodo para detectar aductos de nucleosomas.
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
BR112016017418A2 (pt) Uso de copolímeros
MX391068B (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina.
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
ECSP15049909A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
TR201906354T4 (tr) Bi̇r hareketli̇ mobi̇lya parçasi i̇çi̇n tahri̇k ci̇hazi
CO2018005755A2 (es) Mezcla hemostática de fibras cortas y largas basadas en celulosa
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
MX2017013013A (es) Estireno funcionalizado con [bis(trihidrocarbilsilil)aminosililo] y un metodo para su preparacion.
NZ733127A (en) Tapered precision blade electrosurgical instrument
MX2018008383A (es) Inmunoterapia contra el cáncer mediada por superantígeno mejorada por inmunopotenciador.
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
BR112018006446A2 (pt) composições lubrificantes e métodos para uso das mesmas
BR112017018436A2 (pt) biomarcadores para pré-eclâmpsia
MX388832B (es) Deteccion especifica de isoformas de clusterina.
CL2020003034A1 (es) Agonistas de tlr7
BR112018015343A2 (pt) oxidação de amido
BR112016001229A2 (pt) Composição de revestimento aquosa com durabilidade melhorada
BR112017020507A2 (pt) composição, e, uso de um derivado de éter de isosorbida